Baxter(US:BAX) Globenewswireยท2025-10-26 13:19Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. related to alleged violations of federal securities laws due to misleading statements about the Novum LVP device, which has been linked to serious malfunctions and patient risks [3][5]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in Baxter between February 23, 2022, and July 30, 2025, to discuss their legal rights [1][3]. - A federal securities class action has been filed against Baxter, with a deadline of December 15, 2025, for investors to seek the role of lead plaintiff [3][7]. Group 2: Allegations Against Baxter - The complaint alleges that Baxter and its executives made false statements and failed to disclose systemic defects in the Novum LVP, which led to malfunctions that could cause serious injury or death [5]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of product withdrawal from the market [5]. Group 3: Stock Impact - The true extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary pause in shipments and installations of the Novum LVP, resulting in a 22.4% drop in stock price, closing at $21.76 [6].